SCHEMBL7083647

SCHEMBL7083647

Cc1ccc(C(=O)NC(C)(C)C)c(Nc2ccc3cn[nH]c3c2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 7/20 0.48
KDR P35968 1/20 0.46
KDM4E B2RXH2 5/20 0.45
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
LMNA P02545 1/20 0.45
MAPT P10636 4/20 0.44
HPGD P15428 2/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.44
MCL1 Q07820 1/20 0.44
ATM Q13315 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
EIF2AK2 P19525 1/20 0.44
MAP4K4 O95819 2/20 0.43
CLK2 P49760 2/20 0.43
DYRK1A Q13627 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7081452 0.88 SYK (0.50) SYKKDRKDM4ENPC1RAB9A
SCHEMBL7081454 0.85 SYK (0.53) SYKKDRKDM4ENPC1RAB9A
SCHEMBL7077410 0.85 SYK (0.52) SYKKDRKDM4ENPC1RAB9A
SCHEMBL7082077 0.83 SYK (0.52) SYKKDRKDM4ENPC1RAB9A
SCHEMBL7081409 0.83 SYK (0.46) SYKKDRKDM4ENPC1RAB9A
SCHEMBL7079215 0.81 KDR (0.56) SYKKDRKDM4ENPC1RAB9A
SCHEMBL7083122 0.81 RPS6KB1 (0.49) SYKKDRKDM4ENPC1RAB9A
SCHEMBL7077567 0.80 PDGFRB (0.52) SYKKDRKDM4ENPC1RAB9A
SCHEMBL7081591 0.79 SYK (0.43) SYKKDRKDM4ENPC1RAB9A
SCHEMBL7079355 0.79 PDGFRB (0.51) SYKKDRKDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608058-B2 Therapeutic composition for hepatitis B, hepatitis C, or acquired immune deficiency syndrome DONG WHA PHARM. IND. CO., LTD. (KR) 2003-08-19 US claimed
US-20030092709-A1 6-Methylnicotinamide derivatives as antiviral agents DONG WHA PHARM. CO., LTD. (KR) 2003-05-15 US claimed
US-6608058-B2 Therapeutic composition for hepatitis B, hepatitis C, or acquired immune deficiency syndrome DONG WHA PHARM. IND. CO., LTD. (KR) 2003-08-19 US disclosed
US-20030092709-A1 6-Methylnicotinamide derivatives as antiviral agents DONG WHA PHARM. CO., LTD. (KR) 2003-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092709-A1 6-Methylnicotinamide derivatives as antiviral agents TPMT, HAVCR2, NNMT SYK 4369/4885KDR 3912/4885KDM4E 1288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.